Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -6 of 6 Show results per page	View Search Criteria \| Help With Results


1.		Study of Combination Immunotherapy for the Generation of HER-2/Neu Specific Cytotoxic T Cells

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				Over 18				Other				6304 G-04-003, NCT00194714

Last Modified: 6/25/2007


2.		Phase II Pilot Study of HER2-Neu Peptide Vaccine in Patients with Recurrent Metastatic Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				NCI-97-C-0118 NCI-T97-0009, T97-0009

Last Modified: 6/25/2007


3.		Phase I Study of HER-2/neu Peptide Based Vaccine with Sargramostim (GM-CSF) as an Adjuvant in Patients with Stage III or IV HER-2/neu Expressing Cancers

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				pre or postmenopausal				Other				UW-100.1 NCI-V97-1259, NCT00003002

Last Modified: 5/1/2001 First Published: 11/1/1999


4.		Phase I Study of Adoptive Immunotherapy With HER-2/neu Vaccine-Sensitized Draining Lymph Node Cells Activated in vitro and Reinfused in Patients with HER-2/neu Overexpressing Advanced Breast Cancer (Summary Last Modified 05/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				NCI				MCV-MCC-9809-1B NCI-T98-0073

Last Modified: 7/1/2001 First Published: 4/1/2000


5.		Phase I Vaccine Study of HER-2/neu Peptides Incorporated into Polyactide-co-glycolide (PLG) Microspheres in Patients With Advanced Stage HER-2/neu Expressing Cancers (Summary Last Modified 07/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				Other				UWASH-103 NCI-V99-1574, NCT00005023

Last Modified: 10/3/2003 First Published: 8/24/2003


6.		Phase I Study of HER-2 Protein AutoVac™ in Women With Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI, Pharmaceutical / Industry				CWRU-030339 PHARMEXA-PMXA-1103, PHARMEXA-PX104.1.6-101, NCT00068614

Select All on One Page